Kinase Profiling Inhibitor Database

This is a searchable database of specificities of 55684 commonly used signal transduction inhibitors. These results have been provided by the International Centre for Kinase profiling within the MRC Protein Phosphorylation Unit at the University of Dundee.

We strongly recommend undertaking kinase profiling of any kinase inhibitor to be used in a biological experiment. It is essential to have a good feel for the specificity of the kinase inhibitor you are working with in order to be able to properly interpret your data.

If you have additional kinase inhibitors that you would like the International Centre for Kinase profiling team to profile for you please contact us here for further details.

If you have any feedback or suggestions on how to improve this resource we welcome your input. Pass on your ideas to us here.

Inhibitor Brutto MW Action Reference Screen Conc % Activity Remaining
NG-25 C29H30F3N5O2 537.58 TAK1 Dzamko N (2012) PLoS ONE 7(6) e39132 10 1371
Eduardo Pauls (2012) Journal of Biological Chemistry 287 23 19216-19228

1.00 10
NIK-Novartis-T1-7   C18H14N6OS 362.41 NIK
US20120214762
0.10 128
NIK-Novartis-T1-7   C18H14N6OS 362.41 NIK
US20120214762
1.00 95
Novartis 12a (PKD1)   C23H29F3N6O3 494.51 PKD1 Meredith E.L. (2010) J.Med.Chem. 53 5422-5438


0.10 107
Novartis 12a (PKD1)   C23H29F3N6O3 494.51 PKD1 Meredith E.L. (2010) J.Med.Chem. 53 5422-5438


10.00 76
NVP-BEZ 235   C30H25Cl2N5O 542.46 PI3K, Akt, mTOR Maira S. Stauffer F. (2008) Mol. Cancer. Ther. 7 1851-1863.

WO2008064093
1.00 115
NVP-BEZ 235   C30H25Cl2N5O 542.46 PI3K, Akt, mTOR Maira S. Stauffer F. (2008) Mol. Cancer. Ther. 7 1851-1863.

WO2008064093
10.00 85
NVP-BEZ 235   C30H25Cl2N5O 542.46 PI3K, Akt, mTOR Maira S. Stauffer F. (2008) Mol. Cancer. Ther. 7 1851-1863.

WO2008064093
0.10 108
NVP-BEZ 235   C30H25Cl2N5O 542.46 PI3K, Akt, mTOR Maira S. Stauffer F. (2008) Mol. Cancer. Ther. 7 1851-1863.

WO2008064093
0.01 113
OSU-03012 C26H19F3N4O 460.45 PDK1 Zhu J. (2004) Cancer Res. 64(12) 4309-18


10.00 80